BioSpace News Archive

Business

Sanofi Continues Site Expansions, Preparing for Future Pandemics

The new factory will include cutting-edge technology, allowing production of three to four vaccines simultaneously, a massive improvement on the current limitation of one vaccine in an industrial site.

April 12, 2021
·
2 min read
·
Kate Goodwin
Business

Biogen and Sage’s Movement Disorder Therapy, SAGE-324 Reduces Tremor Score in Study

Recently announced topline results from a Phase II study show SAGE-324, Sage Therapeutics’ investigational oral neuroactive steroid GABAA receptor positive allosteric modulator, significantly reduced tremor score in adult patients with essential tremor.

April 12, 2021
·
3 min read
·
Brandon May
Drug Development

Regeneron’s Antibody Cocktail Cuts Progression to Symptomatic COVID-19

Regeneron Pharmaceuticals announced the results from its Phase III trial of recently infected asymptomatic COVID-19 patients for its REGEN-COV (casirivimab with imdevimab) antibody cocktail.

April 12, 2021
·
3 min read
·
Mark Terry
Drug Development

AstraZeneca’s Diabetes Drug Farxiga Falls Short in COVID-19 Study

AstraZeneca’s diabetes drug Farxiga (dapagliflozin) failed to reach endpoints in a Phase III study as a potential treatment for hospitalized COVID-19 patients serious risk of developing complications.

April 12, 2021
·
3 min read
·
Alex Keown
Drug Development

Large-Scale Study Finds One-Third of COVID-19 Patients Suffer Neurological Damage

Six months after a COVID-19 diagnosis, more than 33% of people exhibited some form of brain damage, according to a study appearing in Lancet Psychiatry.

April 12, 2021
·
4 min read
·
Gail Dutton
Drug Development

mRNA Tech Used in COVID-19 Vaccines Could be Used to Cure HIV, Cancer and More

Researchers are leveraging the messenger RNA (mRNA) technology used to develop the Pfizer-BioNTech and Moderna COVID-19 vaccines for possible treatments for a range of other diseases, including HIV and cancer.

April 12, 2021
·
4 min read
·
Mark Terry
Lone Star Bio

Taysha Dishes Out $5.5 Million for Rare Disease Gene Therapy

Taysha Gene Therapies has acquired exclusive global rights to TSHA-120, an intrathecally dosed AAV9 gene therapy designed to treat giant axonal neuropathy.

April 12, 2021
·
4 min read
·
Brandon May
Drug Development

AACR: BMS Checkpoint Inhibitor Flexes Muscle in Early-Stage Lung Cancer and Other Highlights

In a flurry of weekend activity, oncology companies showcased the latest clinical and preclinical data for cancer therapies during the virtual American Association for Cancer Research meeting.

April 12, 2021
·
5 min read
·
Alex Keown
AACR: OncoMyx Presents First Data Showing Myxoma Virotherapy Anti-Tumor Efficacy

The three posters OncoMyx Therapeutics presented at the virtual American Association for Cancer Research (AACR) Virtual Annual Meeting on April 10th provided the first data indicating its myxoma virotherapy approach to oncolytic therapeutics.

April 12, 2021
·
4 min read
·
Gail Dutton
Global Lung Cancer Diagnostics Market Set to Expand at 7.3% CAGR through 2021: Fact.MR

Growing cases of lung cancer and novel product launches to offer precise diagnosis are the key factors creating growth opportunities

April 12, 2021
·
6 min read